Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung

Journal of Neuro-Oncology

Volumn 115, Issue 1, 2013, Pages 95-101

  Lee, Youngjoo ^a   Han, Ji Youn ^a   Kim, Heung Tae ^a   Yun, Tak ^a   Lee, Geon Kook ^a   Kim, Hyae Young ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Adenocarcinoma; EGFR mutation; EGFR tyrosine kinase inhibitor; Leptomeningeal metastasis; Never smoker; Non small cell lung cancer

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EGFR GENE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LONGITUDINAL STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MENINGEAL METASTASIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEVER SMOKER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SMOKING HABIT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREND STUDY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84885469577     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1199-y     Document Type: Article

References (19)

1. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103-119
2. Chamberlain MC, Kormanik P (1998) Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55:506-512
3. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, De Angelis LM, Omuro AM (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7:382-385
4. Park JH, Kim YJ, Lee K, Kim JH, Bang S, Chung J, Lee JS (2012) Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 76:387-392
5. Lynch TJ et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
6. Rosell R et al (2011) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet oncology 13:239-246
7. Mitsudomi T et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet oncology 11:121-128
8. Rosell R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet oncology 13:239-246
9. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with non-small cell lung carcinoma after response to gefitinib. Cancer 103:2344-2348
10. Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, Kim J, Cho BC (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nons-mall-cell lung cancer. Cancer 116:1336-1343
11. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE (2010) Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16:5873-5882
12. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57:359-364
13. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15:1042-1047
14. Gleissner B, Chamberlain MC (2006) Neoplastic meningitis. Lancet Neurol 5:443-452
15. Han JY et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122-1128
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
17. Lee DH et al (2007) Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60:881-884
18. Kesari S, Batchelor T (2003) Leptomeningeal metastases. Neurol Clin 21:25-66
19. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 12:1193-1199